Status: Completed,
Condition Summary: Dry Eye Disease
Uncategorized
Glaukos reports $31.9 million net loss in second quarter
Glaukos reported a net loss of $31.9 million, or $10.96 per diluted share, in the second quarter compared with a net loss of $2.1 million, or $0.90 per diluted share, in the same quarter of 2014, according to a press release. Net sales totaled $17.8 mi…
Allergan Recalls Contaminated Eye Ointments
Customers reported discovering a black particle that caused superficial eye injury, pain, swelling, and blurred vision. News Alerts
Women, Minorities Still Underrepresented in Medicine
(MedPage Today) — Wide variation seen among specialties
Dr. George Lasezkay Joins Acucela as Executive Vice President, Legal Affairs
SEATTLE–(BUSINESS WIRE)–Acucela Inc. (TOKYO: 4589) (“Acucela” or the “Company”), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, announced today that it has hired Dr. George Lasezkay as Executive Vice President, Legal Affairs, effective Aug. 24. Dr. Lasezkay will head up Acucela’s legal team and be the primary legal advisor to CEO Ryo Kubota and t
Ultrasound-Based Vasculitis Diagnosis May Save Vision (CME/CE)
(MedPage Today) — Fast-track outpatient clinic for giant cell arteritis also cuts inpatient days